Dosage notes
KLOW peptide dosage needs evidence for the actual blend
A precise-looking amount can feel reassuring. I want to know what it came from, because a study of one ingredient doesn’t give us a human schedule for four.

There’s no established human blend schedule
No controlled human trial has established a KLOW dose or frequency for hair growth. There’s no FDA-approved KLOW label with a standard schedule, either.
The total in a container tells you what it holds. It doesn’t tell you what amount belongs in someone’s care. Repeating an online schedule doesn’t fill that gap, however familiar the numbers become.
The ingredients can also leave the body at different rates. That’s another reason a shared preparation doesn’t automatically produce one sensible schedule. The combination still needs its own evidence.
What researchers used, in context
In the rat Achilles tendon study, researchers gave injured rats 10 micrograms, 10 nanograms or 10 picograms of BPC-157 per rat, once daily by injection into the abdominal cavity. Those were animal experiments, not human dosing instructions.
In the human hair trial involving GHK, researchers tested a scalp preparation combining GHK with 5-aminolevulinic acid at 50 or 100 milligrams per millilitre. That concentration belongs to that different preparation. It isn’t a KLOW injection schedule.
For TB-500, FDA found no published study giving it to people. Research on full-length thymosin beta-4, the larger protein, doesn’t establish a dose for its smaller TB-500 fragment.
The prescription decision
Promise Peptides (mypromise.com) offers KLOW peptide care. This care is limited to the United States. A U.S.-licensed clinician reviews your case and decides whether to prescribe; the clinician may decline care. Compounded medicines are not FDA-approved.
A clinician’s decision and proof of a hair benefit answer different questions. FDA explains that compounded drugs are not FDA-approved. Having a prescription doesn’t change that.
On FDA’s page current as of April 22, 2026, BPC-157, KPV, TB-500 and injectable GHK-Cu are “nominated but withdrawn.” Their nominations were taken back. That isn’t clearance or permission to compound, and FDA doesn’t give a separate change date for each substance.
Questions a number can’t answer
- Which exact preparation and route are being considered?
- What evidence applies to my concern?
- How does my medical history affect the discussion?
- How would benefit, unwanted effects and reasons to stop be assessed?
The dosage and frequency questions cover the same distinctions in a quick question-and-answer format.